Christopher L. Kepley

Professor Kepley has a comprehensive biology research background and is recognized internationally for his work, much of which he has shared in 90 peer-reviewed publications. In business, Dr. Kepley was the Group Leader of NanoBiology at Luna Innovations, where he increased revenue by $2 million during his three years as a full-time executive. His inventions have resulted in 11 issued patents for products in active commerce, notably, the first basophil-specific antibody (2D7) currently sold through several biotech companies. Dr. Kepley holds a tenured professorship at the Joint School of Nanoscience and Nanoengineering. He has a BS in Biology, a PhD from Medical College of Virginia, and an MBA from the College of William and Mary.